Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.01 USD
Change Today -0.02 / -1.94%
Volume 90.6K
BIOD On Other Exchanges
Symbol
Exchange
BIOD is not on other exchanges.
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

biodel inc (BIOD) Key Developments

Biodel Inc. Presents at 2nd Annual ROTH Healthcare Day, Jun-24-2015

Biodel Inc. Presents at 2nd Annual ROTH Healthcare Day, Jun-24-2015 . Venue: The Dorchester, 53 Park Lane, Mayfair, London, W1K 1QA, UK, United Kingdom. Speakers: Errol B. De Souza, Chief Executive Officer, President and Director.

Biodel Inc. Announces the Initiation of a Phase 2b Clinical Trial of BIOD-531

Biodel Inc. announced the initiation of a Phase 2b clinical trial of BIOD-531, the company's concentrated, proprietary, recombinant human insulin (RHI) based ultra-rapid-acting prandial/basal combination insulin candidate. The Phase 2b trial, Study 3-250, is a randomized, open-label, parallel group study in patients with insulin-treated type 2 diabetes. Approximately 130 patients are targeted for enrollment at 25 U.S. investigative centers. Patients will be randomized to receive either BIOD-531 or Humalog(R) Mix 75/25 dosed twice daily. Patients will be treated for 18 weeks, the first six weeks of which will focus on active dose titration. The primary analysis will evaluate change from baseline in HbA1c, while secondary endpoints will compare postprandial glucose excursions, hypoglycemic event rates and weight changes. Top line results are expected in mid-2016.

Biodel Inc. Appoints Arlene M. Morris to its Board of Directors

Biodel Inc. announced the appointment of Ms. Arlene M. Morris to its board of directors. Ms. Morris was recently the President and CEO of Syndax. Previously, she was the president, chief executive officer and member of the board of directors of Affymax Inc. Prior to Affymax, Ms. Morris was the president and CEO of Clearview Projects.

Biodel Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2015

Biodel Inc. reported unaudited consolidated earnings results for the second quarter and six months ended March 31, 2015. For the quarter, the company reported loss before tax provision of $4,355,000 against $6,194,000 a year ago. Net loss was $4,356,000 or $0.18 per basic and diluted share against $6,198,000 or $0.29 per basic and diluted share a year ago. For the six months, the company reported loss before tax provision of $9,040,000 against $8,631,000 a year ago. Net loss was $9,043,000 or $0.40 per basic and diluted share against $8,640,000 or $0.41 per basic and diluted share a year ago.

Biodel Inc. to Report Q2, 2015 Results on May 06, 2015

Biodel Inc. announced that they will report Q2, 2015 results at 5:00 PM, US Eastern Standard Time on May 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOD:US $1.01 USD -0.02

BIOD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abeona Therapeutics Inc $6.45 USD +0.45
View Industry Companies
 

Industry Analysis

BIOD

Industry Average

Valuation BIOD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIODEL INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.